The firm is also considering a US regulatory submission of its QiAcuityDx system along with a companion diagnostic test.

The test uses machine learning to analyze biomarkers and clinical features to determine prostate cancer aggressiveness.

The ruling ensures continued coverage, without patient cost-sharing, of services including BRCA testing and colorectal cancer screening, potentially impacting firms like Exact Sciences.

The company plans to bring to market in the coming years a series of microarray-based tests for autoimmune diseases and allergies, among other tests.

The Helsinki-based firm's test is used to automate breast cancer grading using AI-developed models, and it is integrated into the firm's breast cancer suite.

The ASM partnered with the US Centers for Disease Control and Prevention on the guidance published this month in Clinical Microbiology Reviews.

The company has reduced the turnaround time to a little over 48 hours for its pathogen-agnostic metagenomic next-generation sequencing test service for CNS infections ...

NEW YORK – The Association for Molecular Pathology on Tuesday published best practice recommendations for the design and validation of clinical tests for homologous recombination deficiency. The ...

The company hopes to complete proof of principle for a companion diagnostic to identify patients with PCa who are likely to need aggressive treatment.